Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia

Psychiatry Research

Volumn 198, Issue 2, 2012, Pages 329-331

  Liu, Haibo ^a   Kang, Yimin ^a   Liang, Jun ^b   Li, Cunbao ^a   Xiu, Meihong ^c   Chen, Dachun ^c   Yang, Fude ^c   Wang, Fang ^c   Wu, Guiying ^d   Haile, Colin N ^d   Kosten, Therese A ^d   Kosten, Thomas R ^c,d,e   Zhang, Xiang Yang ^c,d,e  

^a INNER MONGOLIA MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c BEIJING HUILONGGUAN HOSPITAL   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immune; Interleukin; Schizophrenia; Tardive dyskinesia

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; MOVEMENT DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84868111610     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.01.002     Document Type: Article

References (17)

1. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophrenia Research 1996, 20:199-203.
2. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Mediators of Inflammation 1993, 2:3-21.
3. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 2008, 21:151-156.
4. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Molecular Neurodegeneration 2009, 4:47.
5. Hoyer K.K., Dooms H., Barron L., Abbas A.K. Interleukin-2 in the development and control of inflammatory disease. Immunological Reviews 2008, 226:19-28.
6. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research 2000, 44:165-175.
7. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. The American Journal of Psychiatry 1993, 150:1408-1410.
8. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
9. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Lin A., Racagni G., Altamura C.A. Effects of a typical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology 2000, 10:119-124.
10. Müller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research 2006, 10:131-148.
11. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
12. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatrica Scandinavica 1994, 90:311-315.
13. Rascol O., Fabre N. Dyskinesia: l-dopa-induced and tardive dyskinesia. Clinical Neuropharmacology 2001, 24:313-323.
14. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982, 39:486-487.
15. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease 2010, 37:510-518.
16. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 2002, 57:247-258.
17. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. The Journal of Clinical Psychiatry 2004, 65:940-947.